Hypoparathyroidism
Conditions
Keywords
Hypoparathyroidism, Teriparatide
Brief summary
Pediatric hypoparathyroidism is an orphan disease. Conventional management combines native and active vitamin D, calcium supplementation and sometimes phosphate binders, with the risk of long term hypercalciuria, nephrocalcinosis and further renal impairment. The use of teriparatide has been reported in adults (daily or bi-daily subcutaneous infusions) and in children (rather continuous subcutaneous infusion) as second-line therapy. The objective of this study is to obtain efficacy and safety data on the use of teriparatide in children with hypoparathyroidism to improve our knowledge of their management.
Interventions
OTHERSerum calcium concentrations results
To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients with hypoparathyroidism * Patients treated with teriparatide * Patients followed in the reference center for calcium and phosphate metabolism diseases of Lyon. * For children under 18: patient and parent (s) / parent having been informed of the study and having expressed their non-opposition
Exclusion criteria
* No social security support
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum calcium concentration | 3 months after treatment initiation |
Secondary
| Measure | Time frame |
|---|---|
| Serum calcium concentration | 1 month after treatment initiation |
Countries
France
Contacts
Primary ContactJustine BACCHETTA, MD
Backup ContactSacha FLAMMIER, PHD
Outcome results
None listed